Comprehensive Bridging Radiotherapy for Limited Pre-CART Non-Hodgkin Lymphoma
Menée à partir de données multicentriques portant sur 100 patients atteints d'un lymphome non hodgkinien, cette étude analyse l'intérêt d'ajouter une radiothérapie "de transition" avant une immunothérapie à base de lymphocytes CAR-T
Chimeric antigen receptor T-cell therapy (CART) for relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) is associated with 30% durable 5-year complete response rates. Most post-CART relapses have a local component (>80%). Bridging radiotherapy (BRT) before CART achieves local control rates of more than 80%. This study reported on the role of comprehensive BRT in limited (<5 involved sites) pre-CART disease.